Relief Therapeutics Holding (Relief Therapeutics Holding) Total Inventories : $0.50 Mil (As of Jun. 2023)

View and export this data going back to 1990. Start your Free Trial

What is Relief Therapeutics Holding Total Inventories?

Relief Therapeutics Holding's total inventories for the quarter that ended in Jun. 2023 was $0.50 Mil. Relief Therapeutics Holding's average total inventories from the quarter that ended in Dec. 2022 to the quarter that ended in Jun. 2023 was $0.37 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Relief Therapeutics Holding's Net-Net Working Capital per share for the quarter that ended in Jun. 2023 was $-1.60.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Relief Therapeutics Holding's Days Inventory for the six months ended in Jun. 2023 was 78.49.

Inventory Turnover measures how fast the company turns over its inventory within a year. Relief Therapeutics Holding's Inventory Turnover for the quarter that ended in Jun. 2023 was 2.33.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Relief Therapeutics Holding's Inventory-to-Revenue for the quarter that ended in Jun. 2023 was 0.11.

Relief Therapeutics Holding Total Inventories Historical Data

The historical data trend for Relief Therapeutics Holding's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding Total Inventories Chart

Relief Therapeutics Holding Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Inventories

Get a 7-Day Free Trial

0.43

0.24

Relief Therapeutics Holding Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Total Inventories	Get a 7-Day Free Trial															0.25	0.43	0.25	0.24	0.50

Relief Therapeutics Holding Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Relief Therapeutics Holding (OTCPK:RLFTF) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Relief Therapeutics Holding's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2023 is

	Net-Net Working Capital Per Share (Q: Jun. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(14.207	+	0.75 * 1.124	+	0.5 * 0.5	-	34.888
-	0	-	0)	/	12.2184
=	-1.60

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Relief Therapeutics Holding's Days Inventory for the six months ended in Jun. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Jun. 2023 )	/	Cost of Goods Sold (Q: Jun. 2023 )	*	Days in Period
	=	0.372	/	0.865	*	365 / 2
	=	78.49

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Relief Therapeutics Holding's Inventory Turnover for the quarter that ended in Jun. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Jun. 2023 )	/	Average Total Inventories (Q: Jun. 2023 )
	=	0.865	/	0.372
	=	2.33

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Relief Therapeutics Holding's Inventory to Revenue for the quarter that ended in Jun. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	0.372	/	3.357
	=	0.11

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Relief Therapeutics Holding Total Inventories Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Relief Therapeutics Holding (Relief Therapeutics Holding) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (OTCPK:RLFTF) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

RLFTY:USA RLFz:UK RLF:Switzerland

Address

Avenue de Secheron 15, Fondation EIP, Batiment, Geneva, CHE, CH-1202

Website

https://www.relieftherapeutics.com

Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Geographically group generates the majority of its revenue from Europe.